Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 4/6 |
Financial Health | 5/6 |
Dividends | 3/6 |
Nanjing Well Pharmaceutical Group Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥21.00 |
52 Week High | CN¥28.60 |
52 Week Low | CN¥17.65 |
Beta | 0.37 |
11 Month Change | 3.75% |
3 Month Change | -18.32% |
1 Year Change | -26.32% |
33 Year Change | 11.94% |
5 Year Change | -7.40% |
Change since IPO | -19.48% |
Recent News & Updates
Nanjing Well Pharmaceutical GroupLtd's (SHSE:603351) Upcoming Dividend Will Be Larger Than Last Year's
Jun 07Little Excitement Around Nanjing Well Pharmaceutical Group Co.,Ltd.'s (SHSE:603351) Earnings
Jun 06Shareholder Returns
603351 | CN Chemicals | CN Market | |
---|---|---|---|
7D | 1.0% | 0.9% | 0.4% |
1Y | -26.3% | -28.6% | -21.0% |
Return vs Industry: 603351 exceeded the CN Chemicals industry which returned -28.6% over the past year.
Return vs Market: 603351 underperformed the CN Market which returned -21% over the past year.
Price Volatility
603351 volatility | |
---|---|
603351 Average Weekly Movement | 4.9% |
Chemicals Industry Average Movement | 5.5% |
Market Average Movement | 5.7% |
10% most volatile stocks in CN Market | 9.0% |
10% least volatile stocks in CN Market | 3.8% |
Stable Share Price: 603351 has not had significant price volatility in the past 3 months.
Volatility Over Time: 603351's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 673 | Renrong Wu | www.well-js.com |
Nanjing Well Pharmaceutical Group Co.,Ltd. focuses on the research and development, production, and sale of pharmaceutical auxiliary materials in China. Its pharmaceutical materials include excipients for injectables and non-injectables.
Nanjing Well Pharmaceutical Group Co.,Ltd. Fundamentals Summary
603351 fundamental statistics | |
---|---|
Market cap | CN¥2.84b |
Earnings (TTM) | CN¥120.49m |
Revenue (TTM) | CN¥1.24b |
23.6x
P/E Ratio2.3x
P/S RatioIs 603351 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
603351 income statement (TTM) | |
---|---|
Revenue | CN¥1.24b |
Cost of Revenue | CN¥915.10m |
Gross Profit | CN¥324.13m |
Other Expenses | CN¥203.63m |
Earnings | CN¥120.49m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 20, 2024
Earnings per share (EPS) | 0.89 |
Gross Margin | 26.16% |
Net Profit Margin | 9.72% |
Debt/Equity Ratio | 27.4% |
How did 603351 perform over the long term?
See historical performance and comparison